Corporate Social Responsibility

At Gilead, we’re advancing new ways to help end the HIV epidemic by delivering innovative therapies to those who need them most. In our latest episode of The Centrifuge Sessions, Magdeleine Hung, Director of Protein Therapeutics, shares insights on our pioneering work in HIV.

GileadNews: We’re joining with Kite Pharma to announce the presentation of transformative cancer research at this year’s American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) annual meetings.

We’re proud to share that “The Adventure Jar,” a children’s book supporting families impacted by metastatic breast cancer (MBC), has received two 2025 Bronze Anvil Awards from the Public Relations Society of America (PRSA).

“Living with primary biliary cholangitis (PBC) can be an isolating experience,” explains Dilek, a mother of two from Germany who suffers from the rare chronic liver disease.

Creating a healthier world for all starts with taking care of the one we all share. As one of America's Greenest Companies, we're always working to ensure our medicines are delivered in ways that safeguard the planet.

At Gilead, we innovate for impact. This commitment helps us drive scientific solutions forward, reach more people in more places and protect the planet we all share.

Congratulations to our very own Tomas Cihlar, Senior Vice President of Research, Virology, for being named to TIME's list of the 100 Most Influential People in the World.

Gilead is committed to using its virology expertise to advance HIV treatment and prevention to help end the epidemic. Since 2010, the company has partnered with Emory University in Atlanta to launch AIDSVu – an online mapping tool that visualizes granular data

At Gilead, we set and achieve bold ambitions in our fight against the world’s most devastating diseases. In this installment of The Centrifuge Sessions, See Phan, Vice President, Oncology Clinical Development